Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Clinical trial NCT04500548 · WITHDRAWN

Trial details

NCT number: NCT04500548
Sponsor: National Cancer Institute (NCI)
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Constitutional Mismatch Repair Deficiency Syndrome Hematopoietic and Lymphoid Cell Neoplasm Lynch Syndrome Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Recurrent Primary Central Nervous System Neoplasm Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Neuroblastoma Refractory Primary Central Nervous System Neoplasm Xeroderma Pigmentosum

Start date: 2021-05-11
Primary completion: 2022-06-21
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.